MMMichal Michal

Michal Michal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michal Michal has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neuroendocrine Differentiation in Synovial Sarcoma—An Immunohistochemical Study of 357 Tumors With 4 Markers: Chromogranin A, Synaptophysin, Insulinoma-associated Protein 1 and Insulin Gene Enhancer Protein ISL-1

    by Maria Del Carmen Rodriguez Pena, Niharika Shah, Mayank Patel, Maciej Kaczorowski, Małgorzata Chłopek, Anna Jasiak, Natálie Klubíčková, Kris Ylaya, Janusz Ryś, Michal Michal, et al.

    Expression of neuroendocrine differentiation (NE) markers in synovial sarcoma may result in misdiagnosis as a neuroendocrine tumor. This investigation evaluated 357 synovial sarcomas to determine the presence of NE markers—chromogranin A (CgA), synaptophysin (SYP), insulinoma-associated protein 1 (INSM1), and insulin gene enhancer protein ISL-1 (ISLET1)—using immunohistochemistry. The cohort included 248 primary tumors, 28 metastases, 4 recurrences, and 77 undetermined lesions. The female-to-male ratio was equal (128/124), and patient ages ranged from 7 to 80 years (median=32). Lower (n=107) and upper (n=50) limbs represented the most frequent sites for primary tumors, while the lung (n=18) was the main site of metastasis. Tumors were classified as monophasic (n=289), biphasic (n=57), and poorly differentiated (n=11). Immunostainings were categorized as diffuse, patchy (≥10% and SSX2 -fusion compared with SSX1 -fusion tumors more frequently expressed NE markers (56.7% vs. 31.7%), but the difference was not statistically significant. In summary, the presence of NE differentiation proteins in certain synovial sarcomas can make diagnosis more difficult, particularly when assessing small biopsy samples where synovial sarcoma is not initially included in the differential diagnosis.

  • Open Access

    Expanding the Molecular-genetic Spectrum of Canalicular Adenoma-like Subtype of Pleomorphic Adenoma of Salivary Glands

    by Natálie Klubíčková, Frederica Loghides, Mari F.C.M. van Den Hout, Valérie Costes-Martineau, Gerardo Ferrara, Miguel Rito, Veronika Msc Hájková, Petr Msc Grossmann, Petr Msc Šteiner, Inka Kovářová, et al.

    Canalicular tumors of the salivary glands have recently emerged as an entity characterized by distinct morphology and recurrent HMGA2 gene rearrangement. In this study, we analyzed 40 cases intending to elucidate their features further. The monophasic or biphasic tumors exhibited a growth pattern of interconnected anastomosing trabeculae and canaliculi, accompanied by a classical pleomorphic adenoma in one-third of the cases. Invasive growth into surrounding adipose tissue was revealed in one case which was, therefore, diagnosed as epithelial-myoepithelial carcinoma. Although the tumor cells uniformly expressed HMGA2 protein in all cases, cytokeratin 7, S100 protein, and SOX10 displayed either diffuse positivity or highlighted the luminal and abluminal cell populations, respectively. Areas with morphological oncocytoid change and AR-immunopositivity of luminal cells were seen in 13/14 (93%) of tested biphasic cases. HMGA2 rearrangement was detected by RNA-sequencing in 30 cases. The most common alteration was an HMGA1::WIF1 fusion, but several novel or rare fusion partners were identified, including ARID2, FHIT, MSRB3 and its antisense variant MSRB3-AS1, IFNG-AS1, and the long intergenic region LINC02389. In addition, FISH revealed HGMA2 break-apart in the remaining 10 cases where targeted sequencing failed to detect any alteration or where RNA sequencing could not be performed. Notably, the loss of the 3’-untranslated region of HMGA2 emerges as the common denominator for the described rearrangements, possibly disrupting its negative regulation by small regulatory RNAs. Awareness of this lesion ensures appropriate diagnosis and clinical management, especially with regard to the possibility of malignant transformation described in this and previous studies.


  • Open Access

    Molecular Profiling of Sinonasal Adenoid Cystic Carcinoma

    by Alena Skálová, Martina Bradová, Abbas Agaimy, Jan Laco, Cécile Badual, Stephan Ihrler, Ivan Damjanov, Niels J. Rupp, Carlos E. Bacchi, Sarina Mueller, et al.

    Adenoid cystic carcinomas (AdCC) of salivary gland origin have long been categorized as fusion-defined carcinomas owing to the almost universal presence of the gene fusion MYB::NFIB, or less commonly MYBL1::NFIB. Sinonasal AdCC is an aggressive salivary gland malignancy with no effective systemic therapy. Therefore, it is urgent to search for potentially targetable genetic alterations associated with AdCC. We have searched the authors’ registries and selected all AdCCs arising in the sinonasal tract. The tumors were examined histologically, immunohistochemically, by next generation sequencing (NGS) and/or fluorescence in situ hybridization (FISH) looking for MYB/MYBL1 and/or NFIB gene fusions or any novel gene fusions and/or mutations. In addition, all tumors were tested for HPV by genotyping using (q)PCR. Our cohort comprised 88 cases of sinonasal AdCC, predominantly characterized by canonical MYB::NFIB (49 cases) and MYBL1::NFIB (9 cases) fusions. In addition, noncanonical fusions EWSR1::MYB; ACTB::MYB; ESRRG::DNM3, and ACTN4::MYB were identified by NGS, each of them in 1 case. Among nine fusion-negative AdCCs, FISH detected rearrangements in MYB (7 cases), NFIB (1 case), and EWSR1 (1 case). Six AdCCs lacked fusions or gene rearrangements, while 11 cases were unanalyzable. Mutational analysis was performed by NGS in 31/88 (35%) AdCCs. Mutations in genes with established roles in oncogenesis were identified in 21/31 tumors (68%), including BCOR (4/21; 19%), NOTCH1 (3/21; 14%), EP300 (3/21; 14%), SMARCA4 (2/21; 9%), RUNX1 (2/21; 9%), KDM6A (2/21; 9%), SPEN (2/21; 9%), and RIT1, MGA, RB1, PHF6, PTEN, CREBBP, DDX41, CHD2, ROS1, TAF1, CCD1, NF1, PALB2, AVCR1B, ARID1A, PPM1D, LZTR1, GEN1, PDGFRA, each in 1 case (1/21; 5%). Additional 24 cases exhibited a spectrum of gene mutations of uncertain pathogenetic significance. No morphologic differences were observed between AdCCs with MYBL1::NFIB and MYB::NFIB fusions. Interestingly, mutations in the NOTCH genes were seen in connection with both canonical and noncanonical fusions, and often associated with high-grade histology or metatypical phenotype, as well as with poorer clinical outcome. Noncanonical fusions were predominantly observed in metatypical AdCCs. These findings emphasize the value of comprehensive molecular profiling in correlating morphologic characteristics, genetic landscape, and clinical behavior in AdCC.


  • Open Access

    Discovery of Novel TULP4/ACTN4/EWSR1/ACTB::MYB and ESRRG::DNM3 Fusions Expands Molecular Landscape of Adenoid Cystic Carcinoma Beyond Fusions Between MYB/MYBL1 and NFIB Genes

    by Alena Skálová, Natálie Klubíčková, Martina Bradová, Abbas Agaimy, Niels J. Rupp, Ivan Damjanov, Georgina Kolnikova, Petr Martínek, Petr Šteiner, Petr Grossmann, et al.

    Adenoid cystic carcinoma (AdCC) is one of the most common salivary gland malignancies and occurs in all major and minor salivary gland and seromucous gland sites. AdCCs of salivary gland origin have long been categorized as fusion-defined carcinomas owing to the almost consistent presence of fusion genes MYB::NFIB, or less commonly MYBL1::NFIB. We collected a cohort of 95 cases of AdCC, which were largely characterized by canonical fusions MYB::NFIB (49 cases) or MYBL1::NFIB (9 cases). In additional 11 cases of AdCC, rearrangements in MYB or NFIB genes were detected by FISH. In addition, NGS revealed novel noncanonical fusion transcripts EWSR1::MYB; ACTB::MYB; ESRRG::DNM3, MYB::TULP4, and ACTN4::MYB, each of them in 1 case. The tumors that showed noncanonical fusions had features of metatypical AdCC with a diverse architecture, lobulated multinodular growth pattern, and hypercellular peripheral palisading of nuclei (2 cases), tubular hypereosinophilia (2 cases), and pale eosinophilic to vacuolated (bubbly) cytoplasm (3 cases). Our study documented 3 cases of AdCC of salivary glands harboring novel gene fusions TULP4::MYB, ACTN4::MYB, and ACTB::MYB, in 1 case each, which have not been described before. A rare EWSR1::MYB fusion was detected in 1 case. Moreover, 1 case of sinonasal metatypical AdCC showed EWSR1 rearrangement detected by FISH. Also, 1 case with an ESRRG::DNM3 fusion of unknown significance is described in this study. These discoveries illustrate how broad molecular profiling will expand understanding of changes in known entities.


  • Extraskeletal myxoid chondrosarcoma: A study of 17 cases focusing on the diagnostic utility of INSM1 expression and presenting rare morphological variants associated with non-EWSR1::NR4A3 fusions

    by Jiří Lenz, Natálie Klubíčková, Nikola Ptáková, Veronika Hájková, Petr Grossmann, Petr Šteiner, Zdeněk Kinkor, Marián Švajdler, Petra Konečná, Dominika Macháčová, et al.


  • Open Access

    A tribute to Prof. Ondrej Hes, MD, PhD (1968–2022)

    by Reza Alaghehbandan, Abbas Agaimy, Leila Ali, Isabel Alvarado-Cabrero, Mahul B Amin, Ludmila Boudova, Anna Caliò, Eva M Comperat, Ivan Damjanov, Ondrej Daum, et al.


  • Open Access

    Mutation Profile Variability in the Primary Tumor and Multiple Pulmonary Metastases of Clear Cell Renal Cell Carcinoma. A Review of the Literature and Analysis of Four Metastatic Cases

    by Kristyna Prochazkova, Nikola Ptakova, Reza Alaghehbandan, Sean R. Williamson, Tomáš Vaněček, Josef Vodicka, Vladislav Treska, Joanna Rogala, Kristyna Pivovarcikova, Kvetoslava Michalova, et al.

    (1) Background: There are limited data concerning inter-tumoral and inter-metastatic heterogeneity in clear cell renal cell carcinoma (CCRCC). The aim of our study was to review published data and to examine mutation profile variability in primary and multiple pulmonary metastases (PMs) in our cohort of four patients with metastatic CCRCC. (2) Methods: Four patients were enrolled in this study. The clinical characteristics, types of surgeries, histopathologic results, immunohistochemical and genetic evaluations of corresponding primary tumor and PMs, and follow-up data were recorded. (3) Results: In our series, the most commonly mutated genes were those in the canonically dysregulated VHL pathway, which were detected in both primary tumors and corresponding metastasis. There were genetic profile differences between primary and metastatic tumors, as well as among particular metastases in one patient. (4) Conclusions: CCRCC shows heterogeneity between the primary tumor and its metastasis. Such mutational changes may be responsible for suboptimal treatment outcomes in targeted therapy settings.